{ "ok": true, "cik": "1847345", "ticker": "ASBP", "name": "ASPIRE BIOPHARMA HOLDINGS, INC.", "filings": [ { "form": "8-K", "filed": "2026-09-09", "items": [ "5.03 Amendments to Articles or Bylaws; Change in Fiscal Year", "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1847345/000149315226041918/0001493152-26-041918-index.htm" }, { "form": "8-K", "filed": "2026-09-08", "items": [ "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1847345/000149315226041725/0001493152-26-041725-index.htm" }, { "form": "8-K", "filed": "2026-08-19", "items": [ "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1847345/000149315226039135/0001493152-26-039135-index.htm" }, { "form": "10-Q", "filed": "2026-08-13", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1847345/000149315226037819/0001493152-26-037819-index.htm" }, { "form": "8-K", "filed": "2026-08-10", "items": [ "1.01 Entry into a Material Definitive Agreement", "2.03 Creation of a Direct Financial Obligation", "3.02 Unregistered Sales of Equity Securities", "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1847345/000149315226036777/0001493152-26-036777-index.htm" }, { "form": "8-K", "filed": "2026-07-20", "items": [ "8.01 Other Events" ], "url": "https://www.sec.gov/Archives/edgar/data/1847345/000149315226033942/0001493152-26-033942-index.htm" } ], "events12m": 24, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001847345.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1847345" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up ASPIRE BIOPHARMA HOLDINGS, INC. ($ASBP). Last filing: 8-K (5.03 Amendments to Articles or Bylaws; Change in Fiscal Year), 2026-09-09. 24 event filings (8-K) in the past twelve months. Auditor change (8-K Item 4.01) filed 2025-09-26.", "auditor": { "changes": [ { "filed": "2025-09-26", "url": "https://www.sec.gov/Archives/edgar/data/1847345/000149315225015773/0001493152-25-015773-index.htm" }, { "filed": "2025-02-21", "url": "https://www.sec.gov/Archives/edgar/data/1847345/000149315225007898/0001493152-25-007898-index.htm" } ], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 6202, "revenueGrowth1y": null, "revenueGrowthPerYear": null, "yearsOfData": 1, "operatingMargin": -3120.1694614640437, "operatingMarginPrior": null, "netMargin": -3947.250564334086, "operatingCashFlow": -4923488, "capitalSpending": null, "freeCashFlow": null, "researchAndDevelopment": 923914, "researchShareOfRevenue": 148.97033215091906, "cash": 1003904, "longTermDebt": null, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2025-12-31", "revenue": 6202 } ], "totalEquity": -6376329, "totalAssets": 1312166, "equityRatio": -4.859392028142781, "returnOnEquity": null, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "range80": null, "ifPaceHeld": null }, "edgarette": "🔖 Exposure: revenue $6K (FY2025). Experience: one year on record; operating margin -312016.9%. Soundness: equity -485.9% of assets (liabilities exceed assets). Credibility: one audited year, little weight. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -312016.9% against a -3.8% median.", "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "summary": "Aspire Biopharma Holdings (ASBP) reported revenue of $0 million in FY2025, operating margin -312017% against a -3.8% median for pharmaceutical preparations, equity -486% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
ASPIRE BIOPHARMA HOLDINGS, INC. against its own record and its peers
Operating marginPeer median -3.8%-312016.9%Equity of assetsPeer median 40.3%-485.9%Gold tick: the median of 118–118 peers with $50M+ revenue in pharmaceutical preparations
", "chartHorizon": null, "backtest": { "tests": 0, "hits": 0, "rate": null, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Aspire Biopharma Holdings (ASBP) reported revenue of $0 million in FY2025, operating margin -312017% against a -3.8% median for pharmaceutical preparations, equity -486% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 6202, "totalDebt": null, "cash": 1003904 }, "experience": { "revenueGrowth1y": null, "revenueGrowthPerYear": null, "operatingMargin": -3120.1694614640437, "operatingMarginPrior": null, "netMargin": -3947.250564334086, "freeCashFlow": null }, "soundness": { "equityRatio": -4.859392028142781, "returnOnEquity": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "credibility": { "auditedYears": 1, "weight": "little", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": { "filed": "2025-09-26", "url": "https://www.sec.gov/Archives/edgar/data/1847345/000149315225015773/0001493152-25-015773-index.htm" } }, "range": null, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001847345.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1847345" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }